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Abstract: Cardiac MR imaging is an effective method for noninvasive imaging of the heart. The technology has been 
limited in the past because of imaging difficulties associated with cardiac motion. In recent years, however, cardiac MR 
imaging has broadened its spectrum of applications in cardiovascular disease with impressive advances in spatial and 
temporal resolution and increased imaging speeds. This review presents the current clinical applications of cardiac MR 
imaging for evaluation of cardiac disease in infiltrative disorders such as amyloidosis, hemochromatosis, and sarcoidosis. 
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BACKGROUND 
  Magnetic resonance imaging (MRI) demonstrates the 
capability to detect cardiac involvement in various infil-
trative disorders at disease presentation and seems to have 
increased possibilities in comparison to computed tomo-
graphy (CT) using both multiplanar and multiechoic 
sequences [1]. Magnetic resonance imaging (MRI) has been 
shown to be an ideal non-invasive tool for imaging and 
diagnosing myocardial and pericardial diseases because it 
combines good spatial resolution, lack of radiation, non-
invasiveness, and three-dimensional imaging with highly 
reproducible measurements. In dilated and hypertrophic 
cardiomyopathy, MRI is suitable for the diagnosis and quan-
tification of ventricular volume, stroke volume, and myo-
cardial mass. Recent developments in the area of fast 
imaging techniques and MR contrast agents rapidly are 
increasing the utility of MRI for studying and assessing 
myocardial diseases. MRI has become a helpful technique to 
diagnose and differentiate infiltrative disorders such as 
amyloidosis, hemochromatosis and sarcoidosis [2].  
  Our review focuses on the value of cardiac MRI in 
various forms of myocardial infiltrative diseases.  
PATHOGENESIS OF INFILTRATIVE DISORDERS 
Hemochromatosis 
  The hallmark of hemochromatosis is the deposition of 
iron in multiple tissue types, most notably the skin, liver, 
pancreas, thyroid, and heart. Cardiac iron deposition may 
cause arrhythmias, congestive heart failure and death in 
patients with primary (Idiopathic) and secondary (acquired) 
hemochromatosis. Onset of heart failure from iron toxicity 
generally results in irreversible cardiac damage. Cardiac 
involvement in primary haemochromatosis is a poor 
prognostic sign and is the main cause of death in the juvenile 
form [3]. Usually, the definitive diagnosis is made by 
subendocardial biopsy in patients with history of primary or 
secondary hemochromatosis. However, the severity can vary  
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considerable among the various cardiac sites in individual 
patients which makes subendocardial biopsy unreliable [4]. 
Non-invasive modalities such as conventional T2 -weighted 
MR sequences can be used routinely to assess the presence 
of iron deposition in the tissues of patients with hemochro-


















Fig. (1). Cardiac MRI Showing Amyloidosis. 
 
 T 2 imaging is highly sensitive in detecting myocardial 
iron deposition, in patients with moderate-to-severe iron 
deposition. In these cases T2 values are substantially reduced 
from the normal values of approximately 50 msec or greater 
to less than 20 msec. When the T2 is less than 20 msec, LV 
systolic function tends to decline progressively, accom-
panied by an increase in LV end-systolic volume index and 
LV mass [6]. The cardiac morbidity to some extent is rever-
sible with standard therapies such as phlebotomy or 
chelation therapy with desferoxamine. Cardiac MRI in Infiltrative Disorders  Current Cardiology Reviews, 2010, Vol. 6, No. 2    135 
Amylidosis 
  Amyloidosis is characterized by the deposition of 
glycoproteins in the extracellular space. Cardiac amyloidosis 
is an interstitial deposition of amyloid fibrils which causes 
concentric thickening of the atrial and ventricular walls, 
where it leads to secondary restrictive cardiomyopathy. 
Involvement of the heart is a common finding and is the 
most frequent cause of death in amyloidosis [7]. It can be 
challenging to differentiate amyloidosis from hypertrophic 
cardiomyopathy, sarcoid and infiltrative lymphoma on 
echocardiography but easy to differentiate on Cardiac MR. 
Deposition of amyloid protein causes changes of tissue 
composition and architecture, and is associated with changes 
in signal intensity on T1-weighted images. Cardiovascular 
magnetic resonance imaging should be considered early in 
the diagnostic work-up of suspected cardiac amyloidosis and 
is useful in monitoring response to treatment [8]. The charac-
teristic features of cardiac amyloidosis by cardiovascular 
magnetic resonance imaging - impaired biventricular systolic 
function, thickened atrioventricular valves, increased atrial 
septal thickness and left ventricular mass, pleural and 
pericardial effusions, and the most impressive finding of 
widespread subendocardial hyperenhancement representing 
infiltration with amyloid protein.Diffuse heterogenous 
enchancement of thickened endocardial myocardium on 
diffuse enchancement on delayed enchancement images 
along with “Zebra” pattern which is biventricular subendo-
caridal enchancement leading to a striped appearance (Fig 2). 
In noninfiltrative  hypertrophic cardiomyopathy, the signal 
intensity of the myocardium is unchanged compared to that 
in healthy subjects. T1 quantification of the heart in patients 










Fig. (2). Cardiac MRI Showing Sarcoid Infiltration. 
Sarcodosis 
  Sarcoidosis is a granulomatous disease of unknown 
etiology that can affect any organ. Cardiac involvement is 
uncommon but has a wide spectrum of clinical manifes-
tations and is potentially fatal [10]. Sudden death accounts 
for over half of the fatalities from cardiac sarcoidosis but the 
mechanism has not been established [11]. Cardiac invol-
vement in sarcoidosis produces symptoms in only 5% of 
patients with sarcoidosis although it has been found in 20–
50% of these patients at autopsy. Diagnosis of cardiac 
sarcoidosis is via myocardial biopsy which is limited as there 
is a possibility of obtaining a false-negative specimen be-
cause of patchy cardiac infiltration [12]. During acute myo-
cardial inflammation sarcoid infiltrates are visible on MRI as 
intramyocardial, epicardial or endocardial hyperenhancement 
in a non-ischemic pattern with increased signal intensity on 
both T2-weighted and early gadapentate dimeglumine-
enhanced images (Fig. 3) .The early initiation of corticos-
teroid therapy prevents malignant arrhythmias and improves 


















Fig. (3). Cardiac MR Images Showing Hemochromatosis. 
DISCUSSION 
  The initial diagnostic imaging modality employed
  in 
assessment of suspected cardiac infiltrative disorders is the 
readily
  available transthoracic echocardiography. This is 
limited in
  its imaging capability by several well-described 
factors such
 as operator experience, restricted field of view, 
and unfavorable
 patient body habitus, potentially leading to 
incomplete assessment
  of an invading cardiac mass. 
Transesophageal echocardiography
 is not limited by issues of 
suitable acoustic windows but is
 an invasive technique and 
has a relatively narrow field of view,
  thus offering only 
limited views of relevant structures, in
 particular the aortic 
arch, inferior vena cava, and left ventricular
 apex [13]. Both 
echocardiographic techniques are limited in their
  ability to 
allow characterization of soft-tissue masses.
  
  Pericardial thickness varies in different regions of the 
heart therefore, its measurement at different levels of the 
right atrium, right ventricle, and left ventricle is recom-
mended. The pericardium adjacent to the right ventricle can 
be visualized in up to 100% of individuals whereas the 
pericardium along the lateral wall of the left ventricle can be 
visualized in only approximately 61% of cases [14]. Gado-
linium-enhanced T1 sequences better delineates the pericar-
dium. Cardiac MR competes with CT as the modality of 
choice in the recognition of unusual disorders. 136    Current Cardiology Reviews, 2010, Vol. 6, No. 2  Neelima Penugonda 
  The advantages of cardiac MR imaging over the more 
widely accessible
 echocardiography are improved resolution 
and soft-tissue contrast,
  greater ability to allow tissue 
characterization, as well as the ability to “phenotype” various 
forms of cardiomyopathy with high spatial resolution and, 
through
 its much larger fields of view, an ability to demons-
trate involvement
  of the adjacent mediastinum and lungs 
[15].
 An added advantage is the reproducible views, which 
allow accurate
 comparison between examinations to evaluate 
any changes in size
 and appearance. Improved non-invasive 
surveillance may also aid in the evaluation of new chemo-
therapeutic agents in treatment of these infiltrative disorders. 
  Disadvantages include the need for electrocardiographic
 
(ECG) gating, which in the presence of arrhythmia, in 
particular
 multiple ectopics, may lead to acquisition artifacts 
and subsequent
 image degradation. The multiplanar assess-
ment of the anatomy, tissue characteristics,
  and functional 
impact of a cardiac or juxtacardiac mass afforded
 by cardiac 
MR imaging should allow early diagnosis thereby avoiding
 
the morbidity associated with late complications. 
CONCLUSIONS 
  Diagnosing cardiac infiltrative disorders can be challeng-
ing but the introduction of cardiac MRI has made early 
diagnosis possible. As outlined in this article, the strength of 
MR imaging is that it can provide flow, function, and in 
some cases metabolic data in a single examination. This is 
crucial as early treatment improves symptoms and prognosis. 
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